Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-05
2006-09-05
Gitomer, Ralph (Department: 1655)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S141000, C514S185000, C514S700000
Reexamination Certificate
active
07101907
ABSTRACT:
The topical administration of statins for the treatment of bone disorders is disclosed.
REFERENCES:
patent: 4870063 (1989-09-01), Binderup et al.
patent: 5021451 (1991-06-01), McLane et al.
patent: 5093363 (1992-03-01), Kita et al.
patent: 5128366 (1992-07-01), Hirai et al.
patent: 5258376 (1993-11-01), Bernstein
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5280040 (1994-01-01), Labroo et al.
patent: 5316765 (1994-05-01), Folkers et al.
patent: 5336687 (1994-08-01), Sabatucci
patent: 5354879 (1994-10-01), Konoike et al.
patent: 5374628 (1994-12-01), Biller
patent: 5403829 (1995-04-01), Lehtinen et al.
patent: 5462932 (1995-10-01), Brenner et al.
patent: 5545661 (1996-08-01), Cullinan
patent: 5604257 (1997-02-01), Tabe et al.
patent: 5840752 (1998-11-01), Henry et al.
patent: 5902805 (1999-05-01), Breton et al.
patent: 5935607 (1999-08-01), Silver
patent: 5965573 (1999-10-01), Petrie et al.
patent: 5968983 (1999-10-01), Kaesemeyer
patent: 6022887 (2000-02-01), Gasper et al.
patent: 6040334 (2000-03-01), Myers et al.
patent: 6080779 (2000-06-01), Gasper et al.
patent: 6083690 (2000-07-01), Harris et al.
patent: 6376476 (2002-04-01), Gasper et al.
patent: 6642216 (2003-11-01), Gasper et al.
patent: 0513760 (1992-11-01), None
patent: 0619305 (1994-10-01), None
patent: 07330613 (1995-12-01), None
patent: WO 93/23034 (1993-11-01), None
patent: WO 96/19501 (1996-06-01), None
patent: WO 97/15308 (1997-05-01), None
patent: WO 97/48694 (1997-12-01), None
patent: WO 98/17267 (1998-04-01), None
patent: WO 98/25460 (1998-06-01), None
patent: WO 99/45923 (1999-09-01), None
patent: WO 01/37876 (2001-05-01), None
Bellows, et al., “Determination of the Capacity for Proliferation and Differentiation of Osteoprogenitor Cells in the Presence and Absence of Dexamethasone,”Develop Biol(Jul. 1990) 140:132-138.
Bilheimer, “Drug Investigation,” (1990) 2 (Suppl. 2) 58-67.
Cui et al. (1997)Clin Orthopaed Related Res344:8-19.
Cui et al., “Lovastatin Prevents Steroid-Induced Adipogenesis and Osteoporosis,” Reports of the ASBMR 18thAnnual Meeting (Sep. 1996)Journal of Bone and Mineral Research(Aug. 1996) 11(Suppl. 1):S510, p. S217.
Ducy et al., “Increased Bone Formation in Osteocalcin-Deficient Mice,”Nature(Aug. 1996) 382:448-452.
Garrett, J. et al. (1999)Journal of Bone and Mineral Research14(Suppl. 1):S180.
Harris et al., “Effects of Transforming Growth Factor β on Bone Nodule Formation and Expression of Bone Morphogenetic Protein 2, Osteocalcin, Osteopontin, Alkaline Phosphatase, and Type I Collagen MrNA in Long-Term Cultures of Fetal Rat Calvarial Osteoblasts,”J Bone Miner Res(Jun. 1994) 9(6):855-863.
Luckman et al., “Nitrogen-Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including Ras,”J Bone Miner Res(1998) 13:581-589.
Luckman et al., “Biophosphonates and Mevastatin Induce Apoptosis in J774 Macrophages by Inhibition of the Mevalonate Pathway,”Bone(1997) 20(4 suppl):114S, XP 008002185.
Mundy, “Regulation of Bone Formation by Bone Morphogenetic Proteins and Other Growth Factors,”Clinical Orthopaedics and Related Research(1996) 323:24-28.
Mundy, “Cytokines and Growth Factors in the Regulation of Bone Remodeling,”J Bone Miner Res(1993) 8(S2):S505-S510.
Mundy, G. et al. (1999)Science286 (5446):1946-1949.
Rickard et al., “Induction of Rapid Osteoblast Differentiation in Rat Bone Marrow Stromal Cell Cultures by Dexamethasone and BMP-2,”Develop Biol(Jan. 1994) 161:218-228.
Stein et al., “Bone Cell Differentiation: a Functionally Coupled Relationship Between Expression of Cell-Growth- and Tissue-Specific Genes,”Current Opinion in Cell Biology(Dec. 1990) 2:1018-1027.
Urist, “Bone: Formation by Autoinduction,”Science(Nov. 1965) 150:893-899.
Wang et al., “Lipid Clearing Agents in Steroid-Induced Osteoporosis,”J Formos Med Assoc(Oct. 1995) 94(10):589-592.
Wozney, “Novel Regulators of Bone Formation: Molecular Clones and Activities,”Science(Dec. 1988) 242:1528-1534.
Wozney, “The Bone Morphogenetic Protein Family and Osteogenesis,” JMolec Reprod Dev(Jun. 1992) 32:160-167.
Baindur Nand
Gasper Shirley R.
Labroo Virender M.
Martinez Theresa
McKernan Patricia A.
Gitomer Ralph
Morrison & Foerster / LLP
OsteoScreen IP, LLC
ZymoGenetics Corporation
LandOfFree
Topical administration of statins for treatment of bone... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical administration of statins for treatment of bone..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical administration of statins for treatment of bone... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3590725